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Effect of linoleic conjugated acid on serum adiponectin levels in patients with COPD 
Abstract: 
Backgraund and abjective: The main characteristic of chronic obstructive pulmonary 
disease (COPD) is a chronic airway and systemic inflammation. Adiponectin secreted by adipose 
tissue and recognized as anti-inflammatory and cardioprotective effects, by stimulating the 
release of other cytokines. Concerning the anti-inflammatory effect of conjugated linoleic acid 
(CLA) supplementation, we investigated the effect of supplementation CLA on serum 
adiponectin in COPD patients.  
Methods: In a double-blind clinical trial, 90 COPD patients were randomly assigned to 
supplementation and control groups (n=45 for each group). In the supplement group, patients 
received 3.2 gr CLA daily for 6 weeks, while those in the control group received placebo. Blood 
sample (3-5 cc) was collected from all subjects before receiving the supplementation or placebo 
and also at the end of the study for analysis of serum adiponectin levels. During the study, their 
dietary intake levels were assessed using the 24-houres dietary recall three days a week at the 
beginning and the end of the study. Also, we compared the CAT score at the beginning and the 
end of study in both groups.  
Results: The adiponectin serum levels significantly increased in the supplement group 
[9.67±2.83 vs. 10.74±3.97, p=0.007] compared to the placebo group [10.28±3.83 vs. 10.79±3.92, 
p=0.22]. In addition, the CAT score results showed that quality of life was improved 
significantly in CLA supplement group (p=0.001).  
Conclusion: CLA supplementation may improve the quality of life of patients with COPD 
by increasing the serum cardioprotective anti-inflammatory cytokines such as 
adiponectin.  
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